Grundinformationen
- Standard-SMILES
CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21- InChIKey
YLCXGBZIZBEVPZ-UHFFFAOYSA-N- Summenformel
- C16H15ClN2
- Durchschnittliche Molmasse
- 270,75 g/mol
- Monoisotopische Masse
- 270,09237616
Überblick
Medazepam is an organic molecular entity.
Namen und Bezeichner
- Bevorzugter Name
- Medazepam
- IUPAC
- 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
- Lokaler Name
- 7-Chlor-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin
- Englischer Name
- MEDAZEPAM
- Summenformel
- C16H15ClN2
- Molmasse
- 270.76
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
2898-12-6- PubChem CID
- 4041
- DTXSID
DTXSID1048708- ChEMBL
CHEMBL28333- ChEBI
CHEBI:31807- UNII
- P0J3387W3S
- EC Number
- 220-783-4
- Nikkaji
- J2.167I
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 4,4
- Polarare Oberfläche (TPSA)
- 15,6 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 2
- Frei drehbare Bindungen
- 1
- Schwere Atome
- 19
- Formalladung
- 0
- Komplexität
- 336
Experimentelle und physikochemische Eigenschaften
Drugs
DEA NFLIS-Drug Category -> Benzodiazepines
DEA Schedule IV Controlled Substance -> Depressants
Pharmaceuticals
Pharmaceuticals -> Benzodiazepines
Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds
Physikochemische Eigenschaften
- Schmelzpunkt
- 95 · 95-97°
- Siedepunkt
- 420.36 °C · 420.36°C (rough estimate)
- Dichte
- 1.1336 · 1.1336 (rough estimate)
- Brechungsindex
- 1.5749 · 1.5749 (estimate)
- storage temp.
- -20 °C · -20°C
- Löslichkeit
- Methanol (Slightly), Water (Slightly)
- Aggregatzustand
- Solid
- pka
- 6.2 · pKa 6.2(H2O) (Uncertain)
- Farbe
- Yellow to Orange
- Wasserlöslichkeit
- 10.83 mg/L · 10.83mg/L(37 ºC)
- Major Application
- clinical testing
- InChI
- 1S/C16H15ClN2.ClH/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19;/h2-8,11H,9-10H2,1H3;1H
- InChIKey
- XBWAZCLHZCFCGK-UHFFFAOYSA-N
- SMILES
- Clc1cc2c(cc1)N(CCN=C2c3ccccc3)C.Cl
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 31 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Toxikologische Informationen
Treatment
General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.
Toxicity Summary
Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Sicherheitsdaten
- wgk
- WGK 2
- ridadr
- 3249
- risk_code
- 22
- Toxizität
- LD50 in mice (mg/kg): 360 i.p., 1070 orally (Randall)
- hazard_code
- Xn
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 3 - Flammable liquids
- Hazard Classifications
- Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
- DEA Controlled Substances
- CSCN: 2836CSA SCH: Schedule IVNARC: No
Chemie und Industrie
Pharmakologische Informationen
ATC Code
N - Nervous system
QN - Nervous system
MeSH Pharmacological Classification
Drugs used to prevent SEIZURES or reduce their severity.
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.
Verwendung und Herstellung
Anwendungen
VerwendenTranquilizer (minor).
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…